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1. Introduction 
Stroke is the third major cause of death in the US. In the past decade there has been an 
exponential growth in modalities to treat acute stroke with acute recanalization therapies, 
including intravenous thrombolysis, intra-arterial chemical thrombolysis and mechanical 
thrombectomy, thromboaspiration, or angioplasty. While these new modalities of therapy 
have been promising, there remains a very real limitation to the overall rate of successful 
recanalization for current standard interventions.  As a result, extrapolation from the cardiac 
literature has lead to early efforts using primary intracranial stenting to achieve safe 
recanalization. A major advantage of intracranial stenting is immediate flow restoration, as 
time to recanalization has repeatedly been shown to be a strong predictor of outcome in 
stroke.  We will provide a cursory review each of the major established methods of acute 
stroke recanalization therapy, followed by a detailed review of intracranial stenting for 
acute stroke recanalization. 
2. Intravenous tPA thrombolysis 
Recombinant tissue-plasminogen activator (rt-PA) has been approved by the FDA for the 
use as a medical therapy in acute stroke. However, only 1% of acute stroke patients’ patients 
in the US receive rt-PA (Barber 2001). The rate of recanalization using intravenous rt-PA is 
around 10%-30% when used within 3 hours of symptoms onset (Wolpert et al 2007). The 
rates of recanalization of large vessels are modest at best. Recanalization of a large internal 
carotid artery occlusion using intravenous rt-PA is around 10% and it can be as high as 30% 
of Middle Cerebral artery occlusion (Wolpert et al 2007) (Saqqur 2007). Recent studies, 
including European Cooperative Acute Stroke Study 3 (ECASS 3), have demonstrated that 
there may be a benefit in administrating intravenous rt-PA up to 4.5 hours from the time of 
onset (Hacke 2008).   
3. Intraarterial tPA thrombolysis 
Large proximal intracranial arteries can be recanalized more effectively with intra-arterial rt-
PA than with intravenous rt-PA (Tomsick 2008). The Prolyse in Acute Cerebral 
Thromboembolism (PROACT) II trial revealed that intra-arterial proukinase within 6 hours 
of onset has 66% recanalization rate but with a higher intracranial hemorrhage 10% versus 
2%. In other words, for every 7 patients that are treated with intraarterial rt-PA, 1 patient 
will benefit (Furlan Jama 1999).  Following the IMS (Interventioanl Managmenet of Stroke) I 
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and II pilot trials, where the combined intervention of both intravenous and intraarterial re-
PA was more effective than the standard intravenous rt-PA alone for patients with NIH 
stroke scale of 10 or worse (IMS II 2007), the IMS III trial is currently underway. The aim of 
the IMS III trial is to enroll 900 patients with NIH stroke scale of 10 or higher and to 
randomize them to IV tPA therapy alone or IV tPA plus intra-arterial rt-PA infusion, MERCI 
thrombus-removal device (see below), Penumbra Aspiration Device (see below) or infusion 
of rt-PA with low intensity ultrasound at the site of the occlusion (Khatri 2008). 
4. Mechanical thrombectomy 
There are multiple mechanical thrombolysis techniques on the market today that treat acute 
stroke. They include Merci retriever (Concentric Medical, Mountain View, CA), snares and 
Alligator (EV3, Irvine, CA). Mechanical Embolus Removal in Cerebral Ischemia (MERCI) 
trial in 2004 revealed a recanalization rate of 64% within 6 hours of onset of stroke when 
used with or without intra-arterial rt-PA (Gobin 2004).  Advancement in device design has 
lead to improved outcome with rate of recanalization exceeding 69% when using intra-
arterial rt-PA as an adjunct to MERCI device (Smith 2008). The use of Snare (Medical Device 
Technologies, Gainesville, Fl) and alligator devices has been limited. Case report and small 
case series have been noted in the literature. For example, Hussain et al (Hussain 2009) 
describes a case series of 7 patients were alligator device was used to remove a clot in a 
straight segment vessels. Of the 7 patients, 5 attempts were successful in retrieving the clot 
with 1 complete recanalization and 4 with partial recanalization.  
5. Thromboaspiration 
Penumbra system (Penumbra, Alameda, CA) has shown to be very effective in acute stroke 
in early studies. One small series reported a revascularization rate of 100% in 21 vessels (20 
patients) (TIMI 2 or 3) when using the Penumbra device (Bose 2008). At 30 days post-
procedure, 45% of the patients had an improvement of 4 point or better on the NIH stroke 
scale with a modified Rankin scale of 2 or better. The mortality rate was high (45%) but was 
not unexpected as the initial NIH stroke scale had a mean of 21 (Bose 2008).  Importantly, 
more comprehensive studies have revealed less successful revascularization rates of 81.6% 
and an increased rate of intracranial hemorrhage, 28% (Penumbra Pivotal Stroke Trial 
Investigators 2009). Additionally concerning was that only a modest number of patients did 
achieve independent outcome at 90 days.  Of interest, there was a higher recanalization rate 
in both internal carotid artery (82.6%) and middle cerebral artery (83%) clots, which suggest 
that the penumbra device might be particularly useful for large vessel occlusions.  
6. Angioplasty 
Balloon angioplasty can augment thrombolysis especially in cases of proximal middle 
cerebral artery occlusion. There are two retrospective studies with 16 total patients revealing 
that the use angioplasty was successful in 10 patients when used followed failure of 
chemical thrombolytic agents (Mori 1999).    Complications of angioplasty include arterial 
dissection and “snow plowing” effect (occlusion of vessel perforators at the ostium by 
plaque displacement) (Levy 2006). Inflating the balloon to 90% of the parent vessel diameter 
has been suggested as a angioplasty technique in order to reduce the potential risk the 
intracranial vessel walls (Levy 2007). 
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7. Intracranial stents 
The use of intracranial stent provides a great benefit of restoring immediate flow to the 
effected area. The evolution of using intracranial stenting for recanalization is a concept that 
is adopted from the cardiac literature.  
Early successful use of balloon-mounted coronary stents, in the setting of acute stroke, has 
advanced the field of intracranial stenting (Levy 2009). Self-expanding stents were first 
introduced in 2002 with a modification designed for intracranial atherosclerosis became 
available later in 2005. Until recently, intracranial stents have been viewed as a reasonable 
“last resort” technique in acute stroke revascularization, however increasing interest has 
developed around using stents as a first-line modality for stroke treatment. 
Despite acute stentings origins being found in the cardiac literature, it is important to note 
that intracranial pathology differs from cardiac pathology in two major ways.  First, cerebral 
arteries lack an extensive external elastic lamina and are relatively fixed in position because 
of small branching and perforating arteries (Lee 2009).  Therefore, any technology used 
intracranially, must be appropriately navigable and atraumatic.  Second, cerebral occlusion 
is often the result of emboli lodged in a healthy vessel, whereas coronary artery occlusion is 
more commonly a product of local vessel disease. This may mean that stenting is of less 
value in acute stroke; however, an alternative hypothesis is that stent placement allows the 
opening of a channel in an embolus while limiting distal emboli and perforator occlusion. 
The first reports of using stents for acute stroke were retrospective series utilizing balloon-
mounted cardiac stents. These achieved a high recanalization rate (79% had TIMI grade 2 or 
3 flow) (Levy 2006). Of the 19 patients that were treated within 6.5 hours of the onset of 
symptoms, 6 died and 1 had asymptomatic intracranial hemorrhage. While these results 
were excellent, in general, balloon-mounted stents are relatively inflexible and are difficult 
to deploy in the anterior circulation.  
The introduction of self-expanding stents has provided, at least a theoretical advantage, by 
decreasing the risk of vessel dissection or rupture and reducing the barotrauma to the 
parent’s vessel (Levy 2006). Advantages of self-expanding stents include easier navigation to 
the target vessel, adaptation to the shape and anatomy of the affected vessel, and reduce rate 
of parent vessel rupture or dissection. The intracranial stents that are currently on the 
market in the US are Neuroform (Stryker Neurovascular, Freemont, CA), Wingspan (Stryker 
Neurovascular, Freemont, CA), and Enterprise (Codman, Raynham, MA). Only Wingspan is 
FDA-approved for the treatment of symptomatic intracranial stenosis, while others are 
indicated for coil assistant treatment. The Neuroform and the wingspan stents are open cell 
design while the Enterprise is a closed cell design. 
Early case reports using the self expanding intracranial specific stents for arterial 
recanalization in 2 adults patients were first published in 2006 (Fitzsimmons 2006, 
Sauvageau 2006). This was followed by a multicenter, retrospective review of intracranial 
stenting for acute stroke in 2007 (Levy 2007) that demonstrated a successful recanalization 
rate of 79% (TIMI 2 or 3) in 18 patients (19 lesions). The use of self –expanding stents 
(Neuroform 16, wingspan 3) with a combination of thrombolysis and angioplasty, MERCI 
device, and/or glycoprotein IIb/IIIa inhibitor had no increased intraprocedural 
complication, however, there were 7 deaths with 4 due to progression of stroke, 2 from 
intracranial hemorrhage and an additional patient suffered respiratory failure. Of note, 7 
patients had an improvement in their NIH scale within 24 hours from the procedure of 4 or 
greater points (Levy 2007). 
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A similar retrospective study of 9 patients who underwent placement of intracranial self-
expanding stent intervention in the setting of acute stroke had recanalization rate of 89% 
(TIMI 2 or 3) (Zaidat 2008). The mean time to treatment was 5.1 hours with successful 
deployment of 9 stents (4 Neuroform, 5 Wingspan). Complications included 3 deaths, 1 
intracrnial hemorrhage and 1 acute in-stent thrombosis that were treated with glycoprotein 
IIb/IIIa inhibitor. All the surviving patients had a good clinical outcome have modified 
Rakin Scale of 2 or better at 90 days follow-up appointment. 
Brekenfeld et al., in a single center retrospective study of self-expanding stents for acute 
stroke achieved 92% recanalization (TIMI 2 or 3) in 12 patients (Brekenfeld 2009). Treatment 
also included the use of thrombolysis, thromboaspiration, thromboembolectomy, and 
angioplasty as well stent placement. Complications included 1 vessel dissection and 4 
deaths but no intracranial hemorrhages. The overall outcome was good in 3 patients 
(modified Rankin Scale of 0-2) and moderate in 3 patients (modified Rankin Scale 3) and 
poor in 6 (modified Rankin Scale of 4-6) at 90 days follow-up.  
Stent-Assisted Recanalization in Acute Ischemic Stroke (SARIS) trial was the first FDA 
approved prospective trial for the use of stenting in the treatment of acute stroke (Levy 2009 
stroke). The patients that were included had poor NIH Stroke scale (mean 14) and were 
treated within 5.5 hours of onset of symptoms. Adjuvant therapy included angioplasty (8), 
intravenous rt-PA (2) and intra-arterial thrombolytics (10). There was 100% recanalization in 
20 patients (Wingspan 17, Enterprise 2, No Deployment 1) and three intracranial 
hemorrhages occurring within 24 hours with one symptomatic hemorrhage. An 
improvement of 4 points or more on NIH stroke scale was achieved in 65% of the patients. 
Sub-acute outcomes demonstrated that 12 patients (60%) had a modified Rankin Scale of 3 
or better at 30 days and additional 5 patients (25%) died of complications related to the 
stroke. More recently Mocco et al. revealed similar results in 20 patients with acute stroke 
were treated with Enterprise stent (Mocco 2010). Of the 20 patients, 10 had received 
intravenous rt-PA, which was unsuccessful. In addition, 12 patients had MERCI retrieval 
attempted, 7 had angioplasty, and 12 had administration of glycoprotein IIb-IIIa 
administration. Three patients had Wingspan stents deployed and one that had an Xpert 
Stent (Abbott, Abbott Park, and IL) deployed. Following the deployment of the Enterprise 
stent there was 100% recanalization with 75% of the patients having improved NIHSS 
(National Institute of Health Stroke Scale) > 4 points. There were 2 patients (10%) with 
symptomatic intracranial hemorrhage.  
8. Intracranial stenting as a temporary measure: 
The use of self-expanding stents as a temporary bypass, thereby allowing vessel 
recanalization while limiting the potential long-term complications that are associated with 
deploying a permanent stent such as in-stent stenosis or complications related to antiplatelet 
therapy. There are early case reports of using this technique in order to re-establish flow in a 
proximal Middle Cerebral artery occlusion despite failure of mechanical thrombolysis and 
chemical thrombolytics administration (Kelly 2008). The partial sheathing of an Enterprise 
stent allows for immediate revascularization of the artery without committing the patient 
for a permanent stent placement. After 20 minutes of blood flow, the stent was removed. 
The patient had a seven point’s improvement to his NIH Stroke Scale following the 
procedure. A similar case was described using partially deployed Enterprise stent for a 
vertebrobasilar occlusion at 9 hours following onset. The patient did have 8 points 
improvement in their NIH stroke scale (Hauk 2009).  
www.intechopen.com
 
Intracranial Stenting for Acute Ischemic Stroke 
 
161 
These early temporary deployment measures have led to further work in developing stent 
based thrombectomy tools, often referred to as “stent-on-a-stick”.  The most utilized of these 
rapidly expanding technology is the Solitaire device (EV3, Irvine, CA).   
The Solitaire was first developed for assistance with wide-neck cerebral aneurysms (Lubicz 
2010). Solitaire stent is a self-expanding stent that can be completely retrieved even when 
fully deployed (Lubicz 2010). A recent European study of 20 anterior circulation stroke 
patients treated within 8 hours of symptom onset with the Solitaire demonstrated a 90% 
revascularization rate, of which 16 had immediate restoration of flow following stent 
deployment (Castano 2010). Complications included 2 (10%) patients with intracranial 
hemorrhage, 4 (20%) died within 90 days. The 90 day follow up revealed that 45% of 
patients had a modified Rankin Scale score of 2 or better. There is also a recent randomized 
clinical trial of Solitaire Stent versus MERCI device, which has been completed, and the data 
is expected shortly. Additionally, there is an ongoing trial to evaluate a newer “stentriever” 
device called the Trevo (Concentric, Mountain View, CA).  It is unknown, at this time, when 
this trial will be completed. 
9. Conclusion 
Acute stroke treatment has developed dramatically over the past decade and a half. 
Endovascular therapies have led to improved recanalization rates, while simultaneously 
extending the therapeutic time window. Recent publications suggest that intracranial stents 
effectively recanalize occluded cerebral blood vessels refractory to traditional techniques 
and, perhaps more excitingly, prospective data collected on the use of intracranial stents as a 
first line therapy have reported recanalization rates approaching 100%, and excellent clinical 
outcomes. While these data, from a highly selected series of patients, are certainly 
encouraging, significant concerns remain regarding the use of intracranial stents for acute 
stroke recanalization.  These include the need for prolonged double antiplatelet therapy and 
continued limitations in the navigability of the current generation of intracranial stents. In 
the coming years we will doubtless see many further advances on the concepts of stent 
based acute stroke recanalization. 
10. References 
Barber, P. A., Zhang, J., Demchuk, A. M., Hill, M. D., & Buchan, A. M. (2001). Why are 
stroke patients excluded from TPA therapy? an analysis of patient eligibility. 
Neurology, 56(8), 1015-1020.  
Bose, A., Henkes, H., Alfke, K., Reith, W., Mayer, T. E., Berlis, A., … Penumbra Phase 1 
Stroke Trial Investigators. (2008). The penumbra system: A mechanical device for 
the treatment of acute stroke due to thromboembolism. AJNR.American Journal of 
Neuroradiology, 29(7), 1409-1413. doi:10.3174/ajnr.A1110  
Brekenfeld, C., Schroth, G., Mattle, H. P., Do, D. D., Remonda, L., Mordasini, P., . . . Gralla, J. 
(2009). Stent placement in acute cerebral artery occlusion: Use of a self-expandable 
intracranial stent for acute stroke treatment. Stroke; a Journal of Cerebral Circulation, 
40(3), 847-852. doi:10.1161/STROKEAHA.108.533810  
Castano, C., Dorado, L., Guerrero, C., Millan, M., Gomis, M., Perez de la Ossa, N., . . . 
Davalos, A. (2010). Mechanical thrombectomy with the solitaire AB device in 
www.intechopen.com
 
Acute Ischemic Stroke 
 
162 
large artery occlusions of the anterior circulation: A pilot study. Stroke; a Journal 
of Cerebral Circulation, 41(8), 1836-1840. doi:10.1161/STROKEAHA.110.584904  
Fitzsimmons, B. F., Becske, T., & Nelson, P. K. (2006). Rapid stent-supported 
revascularization in acute ischemic stroke. AJNR.American Journal of Neuroradiology, 
27(5), 1132-1134.  
Furlan, A., Higashida, R., Wechsler, L., Gent, M., Rowley, H., Kase, C., . . . Rivera, F. (1999). 
Intra-arterial prourokinase for acute ischemic stroke. the PROACT II study: A 
randomized controlled trial. prolyse in acute cerebral thromboembolism. JAMA : 
The Journal of the American Medical Association, 282(21), 2003-2011.  
Gobin, Y. P., Starkman, S., Duckwiler, G. R., Grobelny, T., Kidwell, C. S., Jahan, R., . . . Saver, 
J. L. (2004). MERCI 1: A phase 1 study of mechanical embolus removal in cerebral 
ischemia. Stroke; a Journal of Cerebral Circulation, 35(12), 2848-2854.  
 doi:10.1161/01.STR.0000147718.12954.60  
Hauck, E. F., Mocco, J., Snyder, K. V., & Levy, E. I. (2009). Temporary endovascular bypass: 
A novel treatment for acute stroke. AJNR.American Journal of Neuroradiology, 30(8), 
1532-1533. doi:10.3174/ajnr.A1536  
Hussain, M. S., Kelly, M. E., Moskowitz, S. I., Furlan, A. J., Turner, R. D.,4th, Gonugunta, V., 
. . . Fiorella, D. (2009). Mechanical thrombectomy for acute stroke with the alligator 
retrieval device. Stroke; a Journal of Cerebral Circulation, 40(12), 3784-3788. 
doi:10.1161/STROKEAHA.108.525618  
IMS II Trial Investigators. (2007). The interventional management of stroke (IMS) II study. 
Stroke; a Journal of Cerebral Circulation, 38(7), 2127-2135.  
 doi:10.1161/STROKEAHA.107.483131  
Kelly, M. E., Furlan, A. J., & Fiorella, D. (2008). Recanalization of an acute middle cerebral 
artery occlusion using a self-expanding, reconstrainable, intracranial microstent as 
a temporary endovascular bypass. Stroke; a Journal of Cerebral Circulation, 39(6), 
1770-1773. doi:10.1161/STROKEAHA.107.506212  
Khatri, P., Hill, M. D., Palesch, Y. Y., Spilker, J., Jauch, E. C., Carrozzella, J. A., . . . 
Interventional Management of Stroke III Investigators. (2008). Methodology of the 
interventional management of stroke III trial. International Journal of Stroke : Official 
Journal of the International Stroke Society, 3(2), 130-137. doi:10.1111/j.1747-
4949.2008.00151.x  
Lee, V. H., Samuels, S., Herbst, T. J., Gallegos, M., Cochran, E. J., Chen, M., . . . Lopes, D. K. 
(2009). Histopathologic description of wingspan stent in acute ischemic stroke. 
Neurocritical Care, 11(3), 377-380. doi:10.1007/s12028-009-9258-0  
Levy, E. I., & Chaturvedi, S. (2006). Perforator stroke following intracranial stenting: A 
sacrifice for the greater good? Neurology, 66(12), 1803-1804.  
 doi:10.1212/01.wnl.0000227198.02597.15  
Levy, E. I., Mehta, R., Gupta, R., Hanel, R. A., Chamczuk, A. J., Fiorella, D., . . . Hopkins, L. 
N. (2007). Self-expanding stents for recanalization of acute cerebrovascular 
occlusions. AJNR.American Journal of Neuroradiology, 28(5), 816-822.  
Levy, E. I., Sauvageau, E., Hanel, R. A., Parikh, R., & Hopkins, L. N. (2006). Self-expanding 
versus balloon-mounted stents for vessel recanalization following embolic 
www.intechopen.com
 
Intracranial Stenting for Acute Ischemic Stroke 
 
163 
occlusion in the canine model: Technical feasibility study. AJNR.American Journal of 
Neuroradiology, 27(10), 2069-2072.  
Levy, E. I., Siddiqui, A. H., Crumlish, A., Snyder, K. V., Hauck, E. F., Fiorella, D. J., . . . 
Mocco, J. (2009). First food and drug administration-approved prospective trial of 
primary intracranial stenting for acute stroke: SARIS (stent-assisted recanalization 
in acute ischemic stroke). Stroke; a Journal of Cerebral Circulation, 40(11), 3552-3556. 
doi:10.1161/STROKEAHA.109.561274  
Lubicz, B., Collignon, L., Raphaeli, G., Bandeira, A., Bruneau, M., & De Witte, O. (2010). 
Solitaire stent for endovascular treatment of intracranial aneurysms: Immediate and 
mid-term results in 15 patients with 17 aneurysms. Journal of Neuroradiology.Journal De 
Neuroradiologie, 37(2), 83-88. doi:10.1016/j.neurad.2010.02.003  
Mocco, J., Hanel, R. A., Sharma, J., Hauck, E. F., Snyder, K. V., Natarajan, S. K., . . . Levy, E. I. 
(2010). Use of a vascular reconstruction device to salvage acute ischemic occlusions 
refractory to traditional endovascular recanalization methods. Journal of 
Neurosurgery, 112(3), 557-562. doi:10.3171/2009.8.JNS09231  
Mori, T., Kazita, K., Mima, T., & Mori, K. (1999). Balloon angioplasty for embolic total 
occlusion of the middle cerebral artery and ipsilateral carotid stenting in an acute 
stroke stage. AJNR.American Journal of Neuroradiology, 20(8), 1462-1464.  
Penumbra Pivotal Stroke Trial Investigators. (2009). The penumbra pivotal stroke trial: 
Safety and effectiveness of a new generation of mechanical devices for clot removal 
in intracranial large vessel occlusive disease. Stroke; a Journal of Cerebral Circulation, 
40(8), 2761-2768. doi:10.1161/STROKEAHA.108.544957  
Saqqur, M., Uchino, K., Demchuk, A. M., Molina, C. A., Garami, Z., Calleja, S., ... 
Lotbust Investigators. (2007). Site of arterial occlusion identified by transcranial 
doppler predicts the response to intravenous thrombolysis for stroke. Stroke; a 
Journal of Cerebral Circulation, 38(3), 948-954.  
 doi:10.1161/01.STR.0000257304.21967.ba  
Sauvageau, E., & Levy, E. I. (2006). Self-expanding stent-assisted middle cerebral artery 
recanalization: Technical note. Neuroradiology, 48(6), 405-408. doi:10.1007/s00234-
006-0077-0  
Smith, W. S., Sung, G., Saver, J., Budzik, R., Duckwiler, G., Liebeskind, D. S., . . . Silverman, 
I. E. (2008). Mechanical thrombectomy for acute ischemic stroke: Final results of the 
multi MERCI trial. Stroke; a Journal of Cerebral Circulation, 39(4), 1205-1212. 
doi:10.1161/STROKEAHA.107.497115  
Tissue plasminogen activator for acute ischemic stroke. the national institute of neurological 
disorders and stroke rt-PA stroke study group. (1995). The New England Journal of 
Medicine, 333(24), 1581-1587. doi:10.1056/NEJM199512143332401  
Tomsick, T., Broderick, J., Carrozella, J., Khatri, P., Hill, M., Palesch, Y., . . . Interventional 
Management of Stroke II Investigators. (2008). Revascularization results in the 
interventional management of stroke II trial. AJNR.American Journal of 
Neuroradiology, 29(3), 582-587. doi:10.3174/ajnr.A0843  
Wolpert, S. M., Bruckmann, H., Greenlee, R., Wechsler, L., Pessin, M. S., & del Zoppo, G. J. 
(1993). Neuroradiologic evaluation of patients with acute stroke treated with 
www.intechopen.com
 
Acute Ischemic Stroke 
 
164 
recombinant tissue plasminogen activator. the rt-PA acute stroke study group. 
AJNR.American Journal of Neuroradiology, 14(1), 3-13.  
Zaidat, O. O., Wolfe, T., Hussain, S. I., Lynch, J. R., Gupta, R., Delap, J., . . . Fitzsimmons, B. 
F. (2008). Interventional acute ischemic stroke therapy with intracranial self-
expanding stent. Stroke; a Journal of Cerebral Circulation, 39(8), 2392-2395. 
doi:10.1161/STROKEAHA.107.510966  
www.intechopen.com
Acute Ischemic Stroke
Edited by Prof. Julio Cesar Garcia Rodriguez
ISBN 978-953-307-983-7
Hard cover, 236 pages
Publisher InTech
Published online 18, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Despite significant technological advances in recent years, their impact on our overall health and social, well-
being is not always clear to see. Perhaps, one of the best examples of this can be highlighted by the fact that
mortality rates as a result of cerebrovascular diseases have hardly changed, if at all. This places
cerebrovascular diseases as one of the most prominent causes of both disability and death. In Cuba, for
instance, a total of 22,000 cases of cerebrovascular diseases are reported each year in a country where life
expectancy should increase to 80 years in the near future. In such a situation, to have a book that includes in a
clear and summarized way, a group of topics directly related to the preclinical investigations advances and the
therapeutic procedures for the cerebrovascular disease in its acute phase constitutes a useful tool for the wide
range of the contributors to this affection's problems solution. In this group is included students, professors,
researchers, and health policy makers whose work represents one of the greatest social and human impact
challenges of the XXI century basic and clinical neurosciences.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ahmad Khaldi and J. Mocco (2012). Intracranial Stenting for Acute Ischemic Stroke, Acute Ischemic Stroke,
Prof. Julio Cesar Garcia Rodriguez (Ed.), ISBN: 978-953-307-983-7, InTech, Available from:
http://www.intechopen.com/books/acute-ischemic-stroke/intracranial-stenting-for-acute-ischemic-stroke
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
